atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,atc_level_05_note,DDD_inhaleaerosol,DDD_inhalepowder,DDD_inhalesolution,DDD_instillsolution,DDD_N,DDD_O,DDD_P,DDD_R,unit_inhaleaerosol,unit_inhalepowder,unit_inhalesolution,unit_instillsolution,unit_N,unit_O,unit_P,unit_R
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA02,cyclopentamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA03,ephedrine,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA04,phenylephrine,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA05,oxymetazoline,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA06,tetryzoline,NA,NA,NA,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA07,xylometazoline,NA,NA,NA,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA08,naphazoline,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA09,tramazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA10,metizoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA11,tuaminoheptane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA12,fenoxazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA13,tymazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA14,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA15,indanazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB01,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB02,naphazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB03,tetryzoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB05,ephedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB06,xylometazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB07,oxymetazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB08,tuaminoheptane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC01,cromoglicic acid,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC02,levocabastine,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC03,azelastine,NA,NA,NA,NA,NA,0.56,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC04,antazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC05,spaglumic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC06,thonzylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC07,nedocromil,NA,NA,NA,NA,NA,10.4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC08,olopatadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC51,"cromoglicic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD01,beclometasone,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD02,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD03,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD04,flunisolide,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD05,budesonide,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD06,betamethasone,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD07,tixocortol,NA,NA,NA,NA,NA,8,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD08,fluticasone,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD09,mometasone,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD11,triamcinolone,NA,NA,NA,NA,NA,0.22,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD12,fluticasone furoate,NA,NA,NA,NA,NA,0.11,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD13,ciclesonide,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD52,"prednisolone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD53,"dexamethasone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD57,"tixocortol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD58,"fluticasone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD59,"mometasone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD60,"hydrocortisone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX01,calcium hexamine thiocyanate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX02,retinol,NA,NA,NA,NA,NA,800,NA,NA,NA,NA,NA,NA,NA,U,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX03,ipratropium bromide,NA,NA,NA,NA,NA,0.24,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX05,ritiometan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX06,mupirocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX07,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX08,framycetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX09,hyaluronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX10,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA01,phenylpropanolamine,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA02,pseudoephedrine,NA,NA,NA,NA,NA,NA,0.24,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA03,phenylephrine,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA51,"phenylpropanolamine, combinations",Refers to phenylpropanolamine,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA52,"pseudoephedrine, combinations",Refers to pseudoephedrine,NA,NA,NA,NA,NA,0.24,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA53,"phenylephrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA01,ambazone,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA02,dequalinium,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA03,dichlorobenzyl alcohol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA05,chlorhexidine,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA06,cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA09,benzethonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA10,myristyl-benzalkonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA11,chlorquinaldol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA12,hexylresorcinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA13,acriflavinium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA14,oxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA15,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA16,benzalkonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA17,cetrimonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA18,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA19,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA20,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA21,octenidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB01,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB02,tyrothricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB03,fusafungine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB04,bacitracin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB30,gramicidin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD01,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD02,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD03,cocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD04,dyclonine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD05,ambroxol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AX,Other throat preparations,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets). The DDD for flurbiprofen is based on lozenges and mouth spray which have equivalent dose recommendations.",R02AX01,flurbiprofen,NA,NA,NA,NA,NA,NA,44,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AX,Other throat preparations,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets). The DDD for flurbiprofen is based on lozenges and mouth spray which have equivalent dose recommendations.",R02AX02,ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AX,Other throat preparations,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets). The DDD for flurbiprofen is based on lozenges and mouth spray which have equivalent dose recommendations.",R02AX03,benzydamine,NA,NA,NA,NA,NA,NA,9,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AA,Alpha- and beta-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are based on the treatment of asthma.",R03AA01,epinephrine,NA,2.24,NA,20,NA,NA,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AB,Non-selective beta-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are based on the treatment of asthma.",R03AB02,isoprenaline,NA,0.64,NA,10,NA,NA,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AB,Non-selective beta-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are based on the treatment of asthma.",R03AB03,orciprenaline,NA,6,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC02,salbutamol,NA,0.8,0.8,10,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC03,terbutaline,NA,2,2,20,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC04,fenoterol,NA,0.6,0.6,4,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC05,rimiterol,NA,1.6,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC06,hexoprenaline,NA,1.5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC07,isoetarine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC08,pirbuterol,NA,1.2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC09,tretoquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC10,carbuterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC11,tulobuterol,NA,1.6,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC12,salmeterol,NA,0.1,0.1,NA,NA,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC13,formoterol,NA,24,24,NA,NA,NA,NA,NA,NA,mcg,mcg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC14,clenbuterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC15,reproterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC16,procaterol,NA,60,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC17,bitolterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC18,indacaterol,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC19,olodaterol,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AH,Combinations of adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK01,epinephrine and other drugs for obstructive airway diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK02,isoprenaline and other drugs for obstructive airway diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK04,salbutamol and sodium cromoglicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK05,reproterol and sodium cromoglicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK06,salmeterol and fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK07,formoterol and budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK08,formoterol and beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK09,formoterol and mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK10,vilanterol and fluticasone furoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK11,formoterol and fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK12,salmeterol and budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK13,salbutamol and beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK14,indacaterol and mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK15,salbutamol and budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL01,fenoterol and ipratropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL02,salbutamol and ipratropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL03,vilanterol and umeclidinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL04,indacaterol and glycopyrronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL05,formoterol and aclidinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL06,olodaterol and tiotropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL07,formoterol and glycopyrronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL08,"vilanterol, umeclidinium bromide and fluticasone furoate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL09,"formoterol, glycopyrronium bromide and beclometasone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL10,formoterol and tiotropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL11,"formoterol, glycopyrronium bromide and budesonide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL12,"indacaterol, glycopyrronium bromide and mometasone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA01,beclometasone,NA,0.8,0.8,1.5,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA02,budesonide,NA,0.8,0.8,1.5,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA03,flunisolide,NA,1,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA04,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA05,fluticasone,NA,0.6,0.6,1.5,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA06,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA07,mometasone,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA08,ciclesonide,NA,0.16,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA09,fluticasone furoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB01,ipratropium bromide,NA,0.12,0.12,0.3,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB02,oxitropium bromide,NA,0.6,NA,4,NA,NA,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB03,stramoni preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB04,tiotropium bromide,"Expressed as tiotropium, delivered dose",NA,10,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB04,tiotropium bromide,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB05,aclidinium bromide,"Expressed as aclidinium, delivered dose",NA,0.644,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB06,glycopyrronium bromide,"Expressed as glycopyrronium, delivered dose",NA,44,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB07,umeclidinium bromide,"Expressed as umeclidinium, delivered dose",NA,55,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB08,revefenacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB54,"tiotropium bromide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BC,"Antiallergic agents, excl. corticosteroids","See comment under R03A. The DDDs are based on the prophylaxis of asthma.DDD for inhalation aerosol and inhalation powder differ in this group, due to differences in dosage recommendations for these dosage forms.",R03BC01,cromoglicic acid,NA,40,80,80,NA,NA,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BC,"Antiallergic agents, excl. corticosteroids","See comment under R03A. The DDDs are based on the prophylaxis of asthma.DDD for inhalation aerosol and inhalation powder differ in this group, due to differences in dosage recommendations for these dosage forms.",R03BC03,nedocromil,NA,8,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BX,"Other drugs for obstructive airway diseases, inhalants",See comment under R03A.,R03BX01,fenspiride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CA,Alpha- and beta-adrenoreceptor agonists,NA,R03CA02,ephedrine,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB01,isoprenaline,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB02,methoxyphenamine,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB03,orciprenaline,NA,NA,NA,NA,NA,NA,60,60,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB51,"isoprenaline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB53,"orciprenaline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC02,salbutamol,NA,NA,NA,NA,NA,NA,12,12,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC03,terbutaline,NA,NA,NA,NA,NA,NA,15,15,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC04,fenoterol,NA,NA,NA,NA,NA,NA,10,NA,10,NA,NA,NA,NA,NA,mg,NA,mg
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC05,hexoprenaline,NA,NA,NA,NA,NA,NA,1.5,1.5,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC06,isoetarine,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC07,pirbuterol,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC08,procaterol,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC09,tretoquinol,NA,NA,NA,NA,NA,NA,9,0.2,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC10,carbuterol,NA,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC11,tulobuterol,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC12,bambuterol,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC13,clenbuterol,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mcg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC14,reproterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC15,formoterol,NA,NA,NA,NA,NA,NA,0.16,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC53,"terbutaline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC63,clenbuterol and ambroxol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CK,Adrenergics and other drugs for obstructive airway diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA01,diprophylline,NA,NA,NA,NA,NA,NA,1,1,1,NA,NA,NA,NA,NA,g,g,g
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA02,choline theophyllinate,NA,NA,NA,NA,NA,NA,0.6,NA,0.6,NA,NA,NA,NA,NA,g,NA,g
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA03,proxyphylline,NA,NA,NA,NA,NA,NA,1.2,1.2,1.2,NA,NA,NA,NA,NA,g,g,g
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA04,theophylline,NA,NA,NA,NA,NA,NA,0.4,0.4,0.4,NA,NA,NA,NA,NA,g,g,g
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA05,aminophylline,NA,NA,NA,NA,NA,NA,0.6,0.6,0.6,NA,NA,NA,NA,NA,g,g,g
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA06,etamiphylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA07,theobromine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA08,bamifylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA09,acefylline piperazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA10,bufylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA11,doxofylline,NA,NA,NA,NA,NA,NA,0.8,0.8,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA12,mepyramine theophyllinacetate,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA20,combinations of xanthines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA51,"diprophylline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA54,"theophylline, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA55,"aminophylline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA57,"theobromine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA74,"theophylline, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB01,diprophylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB02,choline theophyllinate and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB03,proxyphylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB04,theophylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB05,aminophylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB06,etamiphylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC01,zafirlukast,NA,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC02,pranlukast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC03,montelukast,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC04,ibudilast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC53,"montelukast, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX01,amlexanox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX02,eprozinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX03,fenspiride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX05,omalizumab,NA,NA,NA,NA,NA,NA,NA,16,NA,NA,NA,NA,NA,NA,NA,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX06,seratrodast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX07,roflumilast,NA,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX08,reslizumab,NA,NA,NA,NA,NA,NA,NA,7.1,NA,NA,NA,NA,NA,NA,NA,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX09,mepolizumab,NA,NA,NA,NA,NA,NA,NA,3.6,NA,NA,NA,NA,NA,NA,NA,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX10,benralizumab,NA,NA,NA,NA,NA,NA,NA,0.54,NA,NA,NA,NA,NA,NA,NA,mg,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX11,tezepelumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA01,tyloxapol,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA02,potassium iodide,NA,NA,NA,NA,NA,NA,1.2,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA03,guaifenesin,NA,NA,NA,NA,NA,NA,0.9,0.9,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA04,ipecacuanha,emetine,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA05,altheae radix,root,NA,NA,NA,NA,NA,1.6,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA06,senega,root,NA,NA,NA,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA07,antimony pentasulfide,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA08,creosote,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA09,guaiacolsulfonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA11,levoverbenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA12,Hederae helicis folium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA13,cineole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB01,acetylcysteine,NA,NA,NA,1.6,NA,NA,0.5,NA,NA,NA,NA,g,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB02,bromhexine,NA,NA,NA,NA,NA,NA,24,24,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB03,carbocisteine,NA,NA,NA,NA,NA,NA,1.5,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB04,eprazinone,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB05,mesna,NA,NA,NA,1.2,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB06,ambroxol,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB07,sobrerol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB08,domiodol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB09,letosteine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB11,stepronin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB13,dornase alfa (desoxyribonuclease),NA,NA,NA,2.5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB14,neltenexine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB15,erdosteine,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB16,mannitol,NA,NA,0.8,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA01,ethylmorphine,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA03,hydrocodone,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA04,codeine,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA05,opium alkaloids with morphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA06,normethadone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA07,noscapine,NA,NA,NA,NA,NA,NA,0.125,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA08,pholcodine,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA09,dextromethorphan,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA10,thebacon,NA,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA11,dimemorfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA12,acetyldihydrocodeine,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB01,benzonatate,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB02,benproperine,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB03,clobutinol,NA,NA,NA,NA,NA,NA,0.12,0.12,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB04,isoaminile,NA,NA,NA,NA,NA,NA,0.11,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB05,pentoxyverine,NA,NA,NA,NA,NA,NA,0.1,NA,0.1,NA,NA,NA,NA,NA,g,NA,g
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB07,oxolamine,NA,NA,NA,NA,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB09,oxeladin,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB10,clofedanol,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB11,pipazetate,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB12,bibenzonium bromide,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB13,butamirate,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB14,fedrilate,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB15,zipeprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB16,dibunate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB17,droxypropine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB18,prenoxdiazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB19,dropropizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB21,cloperastine,Expressed as cloperastine hydrochloride,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB22,meprotixol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB23,piperidione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB24,tipepidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB25,morclofone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB26,nepinalone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB27,levodropropizine,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB28,dimethoxanate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB29,gefapixant,NA,NA,NA,NA,NA,NA,90,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FA,Opium derivatives and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FA01,opium derivatives and mucolytics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FA,Opium derivatives and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FA02,opium derivatives and expectorants,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FB,Other cough suppressants and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FB01,cough suppressants and mucolytics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FB,Other cough suppressants and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FB02,cough suppressants and expectorants,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05X,OTHER COLD PREPARATIONS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA01,bromazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA02,diphenhydramine,NA,NA,NA,NA,NA,NA,0.2,NA,0.2,NA,NA,NA,NA,NA,g,NA,g
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA04,clemastine,NA,NA,NA,NA,NA,NA,2,2,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA06,chlorphenoxamine,NA,NA,NA,NA,NA,NA,80,80,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA07,diphenylpyraline,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA08,carbinoxamine,NA,NA,NA,NA,NA,NA,16,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA09,doxylamine,NA,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA10,trimethobenzamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA11,dimenhydrinate,NA,NA,NA,NA,NA,NA,0.3,NA,0.3,NA,NA,NA,NA,NA,g,NA,g
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA52,"diphenhydramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA54,"clemastine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA56,"chlorphenoxamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA57,"diphenylpyraline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA59,"doxylamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA61,"dimenhydrinate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB01,brompheniramine,NA,NA,NA,NA,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB02,dexchlorpheniramine,NA,NA,NA,NA,NA,NA,6,6,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB03,dimetindene,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB04,chlorphenamine,NA,NA,NA,NA,NA,NA,12,12,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB05,pheniramine,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB06,dexbrompheniramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB07,talastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB51,"brompheniramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB52,"dexchlorpheniramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB54,"chlorphenamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB56,"dexbrompheniramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC01,mepyramine,NA,NA,NA,NA,NA,NA,0.2,0.2,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC02,histapyrrodine,NA,NA,NA,NA,NA,NA,80,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC03,chloropyramine,NA,NA,NA,NA,NA,NA,0.15,20,NA,NA,NA,NA,NA,NA,g,mg,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC04,tripelennamine,NA,NA,NA,NA,NA,NA,0.15,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC05,methapyrilene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC06,thonzylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC52,"histapyrrodine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC53,"chloropyramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD01,alimemazine,NA,NA,NA,NA,NA,NA,30,30,NA,NA,NA,NA,NA,NA,mg,mg,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD02,promethazine,NA,NA,NA,NA,NA,NA,25,25,25,NA,NA,NA,NA,NA,mg,mg,mg
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD03,thiethylperazine,NA,NA,NA,NA,NA,NA,13,13,13,NA,NA,NA,NA,NA,mg,mg,mg
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD04,methdilazine,NA,NA,NA,NA,NA,NA,16,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD05,hydroxyethylpromethazine,NA,NA,NA,NA,NA,NA,75,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD06,thiazinam,NA,NA,NA,NA,NA,NA,0.9,NA,0.3,NA,NA,NA,NA,NA,g,NA,g
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD07,mequitazine,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD08,oxomemazine,NA,NA,NA,NA,NA,NA,30,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD09,isothipendyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD52,"promethazine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD55,"hydroxyethylpromethazine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE01,buclizine,NA,NA,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE03,cyclizine,NA,NA,NA,NA,NA,NA,0.1,0.1,0.3,NA,NA,NA,NA,NA,g,g,g
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE04,chlorcyclizine,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE05,meclozine,NA,NA,NA,NA,NA,NA,50,NA,50,NA,NA,NA,NA,NA,mg,NA,mg
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE06,oxatomide,NA,NA,NA,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE07,cetirizine,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE09,levocetirizine,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE51,"buclizine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE53,"cyclizine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE55,"meclozine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AK,Combinations of antihistamines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX01,bamipine,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX02,cyproheptadine,NA,NA,NA,NA,NA,NA,12,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX03,thenalidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX04,phenindamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX05,antazoline,NA,NA,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX07,triprolidine,NA,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX08,pyrrobutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX09,azatadine,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX11,astemizole,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX12,terfenadine,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX13,loratadine,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX15,mebhydrolin,NA,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX16,deptropine,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX17,ketotifen,NA,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX18,acrivastine,NA,NA,NA,NA,NA,NA,24,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX19,azelastine,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX21,tritoqualine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX22,ebastine,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX23,pimethixene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX24,epinastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX25,mizolastine,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX26,fexofenadine,NA,NA,NA,NA,NA,NA,0.12,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX27,desloratadine,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX28,rupatadine,NA,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX29,bilastine,NA,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,NA,NA,NA,mg,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX31,quifenadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX32,sequifenadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX53,"thenalidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX58,"pyrrobutamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AA,Lung surfactants,"The DDDs of colfosceril palmitate and natural phospholipids are based on the treatment of respiratory distress syndrome in neonates, and correspond to the treatment of children weighing 1.6 kg.",R07AA01,colfosceril palmitate,NA,NA,0.108,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AA,Lung surfactants,"The DDDs of colfosceril palmitate and natural phospholipids are based on the treatment of respiratory distress syndrome in neonates, and correspond to the treatment of children weighing 1.6 kg.",R07AA02,natural phospholipids,NA,NA,NA,NA,0.16,NA,NA,NA,NA,NA,NA,NA,g,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AA,Lung surfactants,"The DDDs of colfosceril palmitate and natural phospholipids are based on the treatment of respiratory distress syndrome in neonates, and correspond to the treatment of children weighing 1.6 kg.",R07AA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB01,doxapram,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,NA,NA,NA,NA,NA,g,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB02,nikethamide,NA,NA,NA,NA,NA,NA,0.5,0.5,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB03,pentetrazol,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB04,etamivan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB05,bemegride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB06,prethcamide,NA,NA,NA,NA,NA,NA,0.4,0.4,NA,NA,NA,NA,NA,NA,g,g,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB07,almitrine,NA,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB08,dimefline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB09,mepixanox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB52,"nikethamide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB53,"pentetrazol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX01,nitric oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX02,ivacaftor,NA,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,NA,NA,NA,g,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX30,ivacaftor and lumacaftor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX31,ivacaftor and tezacaftor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX32,"ivacaftor, tezacaftor and elexacaftor",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
